Sanofi is to abandon its breast cancer candidate amcenestrant, a contender in the oral selective estrogen receptor degrader (SERD) field, after a second late-stage study failure.
The decision follows an interim analysis of the Phase III AMEERA-5 trial of the drug used in tandem with Pfizer’s Ibrance (palbociclib) as a first-line treatment for patients with estrogen receptor-positive
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?